Fulcrum Therapeutics (FULC) 주식 개요
임상 단계의 바이오 제약 회사인 펄크럼 테라퓨틱스는 미국에서 미충족 의료 수요가 높은 유전적 질환 환자의 삶을 개선하기 위한 저분자 의약품을 개발하는 회사입니다. 자세히 보기
FULC Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fulcrum Therapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$3.80 |
| 52주 최고가 | US$15.74 |
| 52주 최저가 | US$2.83 |
| 베타 | 2.58 |
| 1개월 변동 | -0.78% |
| 3개월 변동 | -1.30% |
| 1년 변동 | -48.99% |
| 3년 변동 | -9.52% |
| 5년 변동 | -86.06% |
| IPO 이후 변동 | -71.85% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Sep 03
FULC: Reverse Merger And Tiny Stake Will Drive Bearish Repricing
Analysts have reduced their price target on Fulcrum Therapeutics to $3.50 from $5.83, citing updated fair value estimates, a slightly higher discount rate, adjusted revenue growth projections, and a lower future P/E assumption. What’s in the News for Fulcrum Therapeutics Slate Medicines, Inc.
내러티브 업데이트 • Aug 17
FULC: Cash And Optionality Review Will Shape Post-Program Restructuring Path
Fulcrum Therapeutics' analyst fair value estimate moved from $16.75 to $4.00 as analysts cut modeled expectations following the discontinuation of pociredir in sickle cell disease and shifted focus toward the company's cash position and ongoing review of alternatives. Analyst Commentary Recent Street research on Fulcrum Therapeutics has shifted sharply following the decision to discontinue pociredir in sickle cell disease, with most firms now treating the stock as primarily a cash and optionality story rather than a late stage development story.내러티브 업데이트 • Aug 03
FULC: Cash-Rich Balance Sheet Will Underpin Post-Program Strategic Review Outcomes
Analysts have reset expectations on Fulcrum Therapeutics, with price targets now clustered in the $3 to $4 range. This reflects the removal of pociredir from models and a focus on the company’s cash position and ongoing review of options.Recent updates
내러티브 업데이트 • Sep 03
FULC: Reverse Merger And Tiny Stake Will Drive Bearish Repricing
Analysts have reduced their price target on Fulcrum Therapeutics to $3.50 from $5.83, citing updated fair value estimates, a slightly higher discount rate, adjusted revenue growth projections, and a lower future P/E assumption. What’s in the News for Fulcrum Therapeutics Slate Medicines, Inc.내러티브 업데이트 • Aug 17
FULC: Cash And Optionality Review Will Shape Post-Program Restructuring Path
Fulcrum Therapeutics' analyst fair value estimate moved from $16.75 to $4.00 as analysts cut modeled expectations following the discontinuation of pociredir in sickle cell disease and shifted focus toward the company's cash position and ongoing review of alternatives. Analyst Commentary Recent Street research on Fulcrum Therapeutics has shifted sharply following the decision to discontinue pociredir in sickle cell disease, with most firms now treating the stock as primarily a cash and optionality story rather than a late stage development story.내러티브 업데이트 • Aug 03
FULC: Cash-Rich Balance Sheet Will Underpin Post-Program Strategic Review Outcomes
Analysts have reset expectations on Fulcrum Therapeutics, with price targets now clustered in the $3 to $4 range. This reflects the removal of pociredir from models and a focus on the company’s cash position and ongoing review of options.Seeking Alpha • Jul 31
Fulcrum Therapeutics: Buy It For The Strategic Reset
Summary Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to reset. Fulcrum is a financially strong company in operational distress, and it's trading below NCAV, making it comparable to issues that have strongly outperformed the market. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 10
FULC: Cash Review And Restructuring Will Drive Future Share Repricing
Fulcrum Therapeutics' analyst fair value estimate has been revised from $25.00 to about $16.75 as analysts factor in widespread rating downgrades and sharply reduced price targets, following the discontinuation of the pociredir program in sickle cell disease and the shift toward a cash-focused review of options. Analyst Commentary Recent research on Fulcrum Therapeutics points to a broad reset in expectations after the discontinuation of pociredir in sickle cell disease, with multiple firms revising ratings and price targets, and several explicitly framing the stock more as a cash-focused situation during the current review of options.내러티브 업데이트 • Jun 26
FULC: Cash-Rich Balance Sheet Will Shape Post-Program Review Outcome
The updated analyst price target for Fulcrum Therapeutics has shifted sharply lower, with the fair value estimate moving from about $19.00 to roughly $5.43. Analysts are factoring in the discontinuation of pociredir in sickle cell disease, class-wide safety concerns around PRC2 inhibitors, and the company's transition into a cash-focused story undergoing a review of alternatives.분석 기사 • Apr 01
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...새로운 내러티브 • Mar 20
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Mar 04
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?분석 기사 • Sep 25
We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...분석 기사 • Apr 04
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...분석 기사 • Dec 23
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...분석 기사 • Nov 08
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Sep 12
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking Alpha분석 기사 • Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...분석 기사 • Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...분석 기사 • Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...주주 수익률
| FULC | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 0.3% | 0.9% | -0.1% |
| 1Y | -49.0% | 48.1% | 11.9% |
수익률 대 산업: FULC은 지난 1년 동안 48.1%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: FULC은 지난 1년 동안 11.9%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| FULC volatility | |
|---|---|
| FULC Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: FULC는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: FULC의 주간 변동성은 지난 1년간 14%에서 4%로 감소했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2015 | 9 | Alex Sapir | www.fulcrumtx.com |
펄크럼 테라퓨틱스는 임상 단계의 바이오 제약 회사로, 미국에서 미충족 의료 수요가 높은 유전적 질환 환자의 삶을 개선하기 위한 저분자 의약품을 개발하고 있습니다. 임상 단계의 제품 후보로는 겸상 적혈구 질환 및 베타 지중해빈혈 치료를 위한 임상 1b상 시험 중인 태아 헤모글로빈 유도제인 포시레디르가 있습니다. 또한 다이아몬드-블랙팬 빈혈, 골수부전 증후군, 새로운 태아 헤모글로빈 유도제, 섬유성 질환 치료를 위한 프로그램도 발굴하고 있습니다.
Fulcrum Therapeutics, Inc. 기초 지표 요약
| FULC 기초 통계 | |
|---|---|
| 시가총액 | US$286.88m |
| 순이익 (TTM) | -US$85.00m |
| 매출 (TTM) | n/a |
0.0x
주가매출비율(P/S)-3.4x
주가수익비율(P/E)FULC는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| FULC 손익계산서 (TTM) | |
|---|---|
| 매출 | US$0 |
| 매출원가 | US$56.10m |
| 총이익 | -US$56.10m |
| 기타 비용 | US$28.90m |
| 순이익 | -US$85.00m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.11 |
| 총이익률 | 0.00% |
| 순이익률 | 0.00% |
| 부채/자본 비율 | 0% |
FULC의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/21 00:22 |
| 종가 | 2026/09/21 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Fulcrum Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |